


Peramivir

Chemical Properties

CAS No. :	330600-85-6
Formula:	C ₁₅ H ₂₈ N ₄ O ₄
Molecular Weight:	328.41
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Peramivir (BCX1812) is a highly selective influenza A and B neuraminidase inhibitor with antiviral activity and anti-cytokine effects, which can be used in the study of novel coronavirus and influenza virus infections.
Targets(IC50)	ERK,Antiviral,STAT,IκB/IKK,JNK,p38 MAPK
In vitro	Peramivir (2-10 μM, 6-12 h) inhibits LPS-induced cytokine release from hPBMCs[4]. Peramivir (0.3125-40 μM, 4 h) is non-toxic to macrophages[4].
In vivo	Peramivir (20-60 mg/kg, intraperitoneal injection, single dose) inhibits LPS-induced cytokine storm, attenuates acute lung injury, and prolongs survival in a mouse model of cytokine storm syndrome [4]. Peramivir (75 mg/kg, intramuscular injection once daily for 7 days) rescued BR/08 lethally attacked BALB scid mice in an immunosuppressed mouse model of influenza B virus infection [5].

Solubility Information

Solubility	DMSO: < 1 mg/mL (insoluble or slightly soluble.), (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.045 mL	15.2249 mL	30.4497 mL
5 mM	0.609 mL	3.045 mL	6.0899 mL
10 mM	0.3045 mL	1.5225 mL	3.045 mL
50 mM	0.0609 mL	0.3045 mL	0.609 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Peramivir (Rapivab): an IV neuraminidase inhibitor for treatment of influenza. *Med Lett Drugs Ther.* 2015 Feb 2;57(1461):17-9.

Sato M, et al. Influenza Viral Load and Peramivir Kinetics after Single Administration and Proposal of Regimens for Peramivir Administration against Resistant Variants. *Antimicrob Agents Chemother.* 2014 Dec 29. pii: AAC.04263-14.

Komeda T, et al. Post-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir (II): A pediatric drug use investigation. *J Infect Chemother.* 2014 Nov 26. pii: S1341-321X(14)00402-4.

Hata A, et al. Safety and efficacy of peramivir for influenza treatment. *Drug Des Devel Ther.* 2014 Oct 24;8:2017-38.

Zhang CX, et al. Peramivir, an Anti-Influenza Virus Drug, Exhibits Potential Anti-Cytokine Storm Effects. *Front Immunol.* 2022 Feb 28;13:856327.

Pascua PNQ, et al. Pathogenicity and peramivir efficacy in immunocompromised murine models of influenza B virus infection. *Sci Rep.* 2017 Aug 4;7(1):7345.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481